Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine
Open Access
- 29 July 2009
- journal article
- research article
- Published by Informa UK Limited in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 24 (5), 1061-1066
- https://doi.org/10.1080/14756360802610761
Abstract
Berberine was investigated as an inhibitor of human dipeptidyl peptidase IV (DPP IV) in an attempt to explain its anti-hyperglycemic activities. The investigation included simulated docking experiments to fit berberine within the binding pocket of DPP IV. Berberine was found to readily fit within the binding pocket of DPP IV in a low energy orientation characterized with optimal electrostatic attractive interactions bridging the isoquinolinium positively charged nitrogen atom (berberine) and the negatively charged acidic residue of glutamic acid-205 (GLU205) of DPP IV. Experimentally, berberine was found to inhibit human recombinant DPP IV in vitro with IC50 = 13.3 μM. Our findings suggest that DPP IV inhibition is, at least, one of the mechanisms that explain the anti-hyperglycemic activity of berberine. The fact that berberine was recently reported to potently inhibit the pro-diabetic target human protein tyrosine phosphatase 1B (h-PTP 1B) discloses a novel dual natural h-PTP 1B/DPP IV inhibitor.Keywords
This publication has 44 references indexed in Scilit:
- Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 DiabetesDiabetes, 2004
- Global Prevalence of DiabetesDiabetes Care, 2004
- Enhancing Incretin Action for the Treatment of Type 2 DiabetesDiabetes Care, 2003
- Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patientsDiabetologia, 2002
- Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2001
- Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker RatsDiabetes, 2001
- New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 DiabetesCell, 2001
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*Journal of Clinical Endocrinology & Metabolism, 1986
- STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN.1Journal of Clinical Endocrinology & Metabolism, 1973